Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

3 Top Healthcare Stocks to Buy Right Now

Three very different stocks with one thing in common: They could all be winners for long-term investors.

Is Amgen a Buy?

There's good news and there's bad news for this big biotech.

Is Auxly Cannabis a Buy?

This marijuana stock has a lot of potential. But that potential has yet to be realized.